Ratings by BofA Securities (Jason Zemansky)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Eikon Therapeutics Inc. | EIKN | New Coverage | Buy (N/A) |
13.78 (14.38) |
4.35% | Details | |
| 2/25/2026 | Cytokinetics | CYTK | Maintain | Neutral (N/A) |
|
Details | ||
| 2/20/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Neutral (N/A) |
|
Details | ||
| 2/20/2026 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 1/21/2026 | Inhibikase Therapeutics Inc | IKT | New Coverage | Buy (N/A) |
1.65 (1.88) |
13.94% | Details | |
| 12/18/2025 | Insulet Corporation | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Neutral (N/A) |
|
Details | ||
| 11/28/2025 | Keros Therapeutics | KROS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/28/2025 | Arcus Biosciences | RCUS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/7/2025 | Arcus Biosciences | RCUS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/20/2025 | Rocket Pharmaceuticals | RCKT | Upgrade | Buy (Neutral) |
2.91 (4.41) |
51.55% | Details | |
| 6/11/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2025 | Keros Therapeutics | KROS | Downgrade | Neutral (Buy) |
15.04 (11.30) |
-24.87% | Details | |
| 5/6/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 4/15/2025 | Cytokinetics | CYTK | Maintain | Neutral (N/A) |
|
Details | ||
| 2/18/2025 | Arcus Biosciences | RCUS | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2025 | Akero Therapeutics | AKRO | Upgrade | Buy (Neutral) |
54.00 (54.74) |
1.37% | Details | |
| 10/24/2024 | Arcus Biosciences | RCUS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/18/2024 | Tyra Biosciences | TYRA | Upgrade | Buy (Neutral) |
25.98 (35.04) |
34.87% | Details | |
| 9/9/2024 | Cytokinetics | CYTK | Maintain | Neutral (N/A) |
|
Details | ||
| 8/15/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2024 | Arcus Biosciences | RCUS | Maintain | Neutral (N/A) |
|
Details | ||
| 7/30/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 6/26/2024 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2024 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2024 | Cytokinetics | CYTK | Maintain | Neutral (N/A) |
|
Details | ||
| 4/3/2024 | Cytokinetics | CYTK | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2024 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2024 | Kura Oncology | KURA | Maintain | Buy (N/A) |
|
Details | ||
| 12/26/2023 | Allovir Inc. | ALVR | Downgrade | Underperform (Buy) |
0.77 (9.81) |
1174.03% | Details | |
| 10/25/2023 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
11.72 (22.07) |
88.31% | Details | |
| 9/6/2023 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 9/5/2023 | Arcus Biosciences | RCUS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/18/2023 | Allovir Inc. | ALVR | New Coverage | Buy (N/A) |
2.47 (9.81) |
297.17% | Details | |
| 8/11/2023 | Kura Oncology | KURA | New Coverage | Buy (N/A) |
11.04 (8.96) |
-18.84% | Details | |
| 7/3/2023 | Reneo Pharmaceuticals | RPHM | New Coverage | Buy (N/A) |
6.56 (1.82) |
-72.26% | Details | |
| 5/10/2023 | Arcus Biosciences | RCUS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2023 | Cytokinetics | CYTK | Maintain | Neutral (N/A) |
|
Details | ||
| 4/24/2023 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2023 | Cytokinetics | CYTK | Maintain | Neutral (N/A) |
|
Details | ||
| 2/17/2023 | Cytokinetics | CYTK | New Coverage | Neutral (N/A) |
44.13 (60.41) |
36.89% | Details | |
| 1/30/2023 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2022 | Arcus Biosciences | RCUS | New Coverage | Neutral (N/A) |
28.74 (22.11) |
-23.07% | Details | |
| 11/18/2022 | Insmed | INSM | New Coverage | Buy (N/A) |
18.53 (140.13) |
656.23% | Details | |
| 2/22/2022 | Homology Medicines | FIXX | Maintain | Buy (N/A) |
|
Details | ||
| 12/22/2021 | Allakos Inc. | ALLK | Downgrade | Underperform (Buy) |
84.39 (0.33) |
-99.61% | Details | |
| 12/13/2021 | Allakos Inc. | ALLK | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2021 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Buy (N/A) |
17.50 (0.63) |
-96.4% | Details |
